---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-040004"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:07:53.137054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relmada provides Phase 3 update for REL-1017 in MDD; cash $132.4M

## Summary
- Cash and equivalents $132.4M as of 3/31/23; ~30.1M common shares outstanding (45.6M as-converted).
- Reliance I and III did not meet primary endpoints; post-hoc analysis with removal of two sites showed -4.1 MADRS difference (p=0.02).
- Key trial improvements: require medical records to verify depression, limit patients per site, simplify assessments.
- Upcoming milestones: complete Reliance II (adjunctive) in 1H 2024; initiate additional Phase 3 adjunctive trial mid-2023, completion 2H 2024.
- No serious treatment-related TEAEs, no abuse potential; safety profile consistent across studies.

## SEC filing metadata
- accession: 0001213900-23-040004
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/0001213900-23-040004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023040004/ea178627-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-040004
- JSON: https://secwatch.observer/filing/0001213900-23-040004.json
- Plain text: https://secwatch.observer/filing/0001213900-23-040004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.